List of Immuno-Assays Companies in Washington - 4

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ research service and kit that is used to answer research questions, as well as to discover new prognostic and diagnostic signals. It also provides clonoSEQ diagnostic tests, which include immunosequencing services for use in the detection and monitoring of minimal residual disease in patients with select blood cancers. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test; and Amgen to develop a therapeutic to prevent or treat COVID-19. It serves the life sciences research, clinical diagnostics, and drug discovery customers. Adaptive Biotechnologies Corporation has a translational collaboration with AstraZeneca to investigate the use of immunoSEQ T-MAP. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was founded in 2009 and is headquartered in Seattle, Washington.

With unrivaled expertise in immunology, 5 operating sites in North America and Europe, and a translational offer of services covering the needs of the pharmaceutical industry from the lead selection to the late clinical stage, Nexelis, a Q² Solutions Company, is a leading provider of assay development and advanced laboratory testing services in the infectious, metabolic and oncologic fields. Our versatile team of scientists, working with state of the art technology platforms, were instrumental in the development, qualification, validation, and large-scale sample testing of assays that supported the FDA filing of almost 350 new molecular entities, including blockbuster vaccines and biologics, anti-viral drugs, immunotherapy, gene and cell therapy products.

Developing a single cell immunoprofiling platform.The company’s tools quantify and assess what types of cells are in samples based on the composition of surface proteins.

SISCAPA technology is the smart shortcut to sensitive quantitation of protein biomarkers and targets. SISCAPA assays combine the precision of MRM mass spectrometry with the power of affinity enrichment to deliver a superior alternative to conventional immunoassays for protein quantitation. The SISCAPA workflow is highly automated and exploits familiar LC-MS/MS platforms widely used for drug and metabolite quantitation. At SAT we believe quantitation of proteins in biologic samples provides an actionable measure of the state of health, disease and treatment. We provide services and products for sequence-specific protein quantitation and robust generation of data in an automated, multiplexed and high throughput manner. Analysis is carried out using a generic workflow, allowing for validation and industrialization of processes for such applications as biomarker validation, protein bioanalysis, pathway research for therapeutic development and monitoring and for use in laboratory-developed tests. SISCAPA assays enable multiplexed quantitation of proteins over many orders of magnitude dynamic range. The generic, automated workflow ensures robust results with high throughput and precision. SISCAPA services include complete Assay Reagent Development or specialized Assay Implementation to maximize your up-time and help you quantitate proteins with unmatched precision. Our pipeline has generated reagents for SISCAPA quantitation of more than 250 different proteins to date, providing an unparalleled experience base.